scispace - formally typeset
Open AccessJournal ArticleDOI

Relevance of HBx for Hepatitis B Virus-Associated Pathogenesis

Anja Schollmeier, +2 more
- 01 Mar 2023 - 
- Vol. 24, Iss: 5, pp 4964-4964
Reads0
Chats0
TLDR
Based on the cellular distribution of hepatitis B virus (HBV) regulatory protein, a review encompasses the current knowledge and previous investigations of HBx in context of cellular signaling pathways and HBV-associated pathogenesis as discussed by the authors .
Abstract
The hepatitis B virus (HBV) counts as a major global health problem, as it presents a significant causative factor for liver-related morbidity and mortality. The development of hepatocellular carcinomas (HCC) as a characteristic of a persistent, chronic infection could be caused, among others, by the pleiotropic function of the viral regulatory protein HBx. The latter is known to modulate an onset of cellular and viral signaling processes with emerging influence in liver pathogenesis. However, the flexible and multifunctional nature of HBx impedes the fundamental understanding of related mechanisms and the development of associated diseases, and has even led to partial controversial results in the past. Based on the cellular distribution of HBx—nuclear-, cytoplasmic- or mitochondria-associated—this review encompasses the current knowledge and previous investigations of HBx in context of cellular signaling pathways and HBV-associated pathogenesis. In addition, particular focus is set on the clinical relevance and potential novel therapeutic applications in the context of HBx.

read more

Citations
More filters
Journal ArticleDOI

HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis

TL;DR: In this article , the authors analyze how interactions between hepatitis B virus and host concur in the mechanisms of infection, persistence, and oncogenesis and what are the implications and the therapeutic perspectives that follow.
Journal ArticleDOI

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

TL;DR: A potential therapeutic strategy to treat conditions brought on by the aberrant production of a disease-causing protein is emerging for targeted protein breakdown using the PROTACs technology as mentioned in this paper .
References
More filters
Journal ArticleDOI

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Theo Vos, +2419 more
- 17 Oct 2020 - 
TL;DR: Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates, and there has been a marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries.
Journal ArticleDOI

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

TL;DR: It is shown that the receptor-binding region of pre-S1 specifically interacts with sodium taurocholate cotransporting polypeptide (NTCP), a multiple transmembrane transporter predominantly expressed in the liver that is a functional receptor for HBV and HDV.
Journal ArticleDOI

Infection of a human hepatoma cell line by hepatitis B virus

TL;DR: A cell line, called HepaRG, is described, which exhibits hepatocyte-like morphology, expresses specific hepatocyte functions, and supports HBV infection as well as primary cultures of normal human hepatocytes, suitable for many applications including drug metabolism studies.
Journal ArticleDOI

Virus-like particles in serum of patients with australia-antigen-associated hepatitis

D. S. Dane, +2 more
- 04 Apr 1970 - 
TL;DR: Virus-like particles about 42 nm in diameter have been found in multiple serum specimens from three Australia-antigen-positive hepatitis patients, and it is suggested that these particles may be complete virus and that the much more numerous 22 nm.
Journal ArticleDOI

HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B

Michael Nassal
- 03 Jun 2015 - 
TL;DR: This review aims to summarise current knowledge on ccc DNA molecular biology, to highlight the experimental restrictions that have hitherto hampered faster progress and to discuss cccDNA as target for new, potentially curative therapies of chronic hepatitis B.
Related Papers (5)